Abstract & Article Details
Research Highlights • Vol.3, Issue 6 • ISSN: 2766-2276 • Open Access • CC BY 4.0
Open Access
Research Highlights
Vol.3, Issue 6 June 30, 2022
Development of a Novel Anti-SARS-CoV-2 Antiviral: Effective Inhibitory Activity of Brilacidin
DOI:
10.37871/jbres1504
Abstract
The race to develop effective therapeutics/therapies against SARS-CoV-2 infections and COVID-19 is ongoing as the pandemic is still far from being controlled. Recently, three groups of scientists including Bakovic, et al. [1], Xu, et al. [2]and Hu, et al. [3] respectively, reported a promising and highly attractive antiviral activity of a new drug, named brilacidin, against SARS-CoV-2 infections.
Research Topics
Get email alerts when new articles are published in these topics
Subscribe for Alerts
How to Cite
Zelia Nelly Ndoutoume, Arnaud John Kombe Kombe* and Fleury Augustin Nsole Biteghe (2022). Development of a Novel Anti-SARS-CoV-2 Antiviral: Effective Inhibitory Activity of Brilacidin. Journal of Biomedical Research & Environmental Sciences, 3(6). https://doi.org/10.37871/jbres1504
Article Information
| Journal | Journal of Biomedical Research & Environmental Sciences (JBRES) |
|---|---|
| ISSN | 2766-2276 |
| DOI | DOI 10.37871/jbres1504 |
| Volume / Issue | Vol. 3, Issue 6 |
| Received | June 27, 2022 |
| Accepted | June 29, 2022 |
| Published | June 30, 2022 |
| Article Type | Research Highlights |
| Pages | 726-728 |
| License | CC BY 4.0 — Open Access |
| Publisher | SciRes Literature LLC, Sheridan, WY, USA |
| Language | English |
Published under CC BY 4.0 — free to share, copy, adapt, and redistribute with attribution.
Certificate of Publication
Certificate verifies that this article was peer-reviewed and published in the Journal of Biomedical Research & Environmental Sciences.